-
Vasculopathy knows no compartmentalization. Clinicians expect that patients with peripheral arterial disease will also commonly have comorbid coronary or cerebrovascular disease, even though it may be silent.
-
Data from the Nurses Health Study revealed that abdominal obesity in females is significantly and positively associated with all-cause and cause-specific mortality and specifically is associated with increased CVD mortality even in normal-weight women.
-
-
Regadenoson, the first selective A2A adenosine receptor agonist, has been approved for use as a pharmacologic stress agent for nuclear medicine stress testing (radionuclide myocardial perfusion imaging).
-
Because the consequence of missed pulmonary embolism (PEM) is so grave, it is essential to continue our evolution of tools which maximize diagnostic sensitivity, offer clinical expedience, and minimize risk for the patient.
-
Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
-
Despite previous positive reports and much lay enthusiasm, omega-3 fatty acid treatment did not prevent Crohn's disease relapse. (Arguments continue as to whether the correct usage should be "Crohn disease" or "Crohn's disease." Most of the literature seems to use the latter designation, and this review will do likewise.)
-
Cognitive impairment in the U.S. population without dementia is found in 22% of those over age 70. This is more than the number of those with Alzheimer's or other dementias alone, and needs to be recognized and addressed in our healthcare of this group.
-
Current use of antipsychotic medications by the elderly places them at increased risk for hospitalization for pneumonia.
